NovaBridge Biosciences
NASDAQ:NBPBiotechnology
-$0.07 today
- Market cap
- $104.10M
- Beta
- 1.48
- P/E (TTM)
- -25.5
- EPS (TTM)
- -$0.40
Volume 0.87M
Average 0.90M
NBP Net Income
Bottom-line profit, the starting point for calculating cash from operations.
NovaBridge BiosciencesNASDAQ: NBP
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income growth accelerates
Q4 FY2025 net income of $72.86M (cash outflow) rose 10.2% year over year, ahead of the -47.8% change in trailing-twelve-month net income. Sequentially, it rose 49.7% from the prior quarter. Over 3 fiscal years it compounded at -67.2% a year.
Context
- Net income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$138.98M (+57.3%) for the fiscal year ending Dec 2026, a step up from the -75.6% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$72.86M+49.7% QoQ
- Last fiscal yearDec 2025
- -$88.34M-75.6% YoY
- LTMSep 2025
- -$150.96M-47.8% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +10.2% | +66.1% | +55.9 pp |
| 1 year | -75.6% | +57.3% | +133.0 pp |
| 3-year CAGR | -67.2% | +36.3% | +103.5 pp |
| 5-year CAGR | +20.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
Mixed currencies · from the cash flow
- Latest · FY2025
- (88.34M) USD
- Year-over-year change
- —
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (88.34M) | — |
| FY2024 | 2024-12-31 | (362.72M) | -74.2% |
| FY2023 | 2023-12-31 | (208.18M) | +91.7% |
| FY2022 | 2022-12-31 | (2.51B) | -7.5% |
| FY2021 | 2021-12-31 | (2.33B) | — |
Net Income vs competitors
How NBP compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -47.8% is the lowest of 10, against a peer median of +18.7%.
- Over three fiscal years its annual growth of -67.2% compares with a peer median of +10.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $209.38M USD | -18.9% | +0.2% | — | |
| LTM Mar 2026 | $196.48M USD | +17.4% | +13.3% | — | |
NBPNovaBridge Biosciences | LTM Sep 2025 | CN¥150.96M CNY | -47.8% | -67.2% | — |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $126.85M USD | +58.8% | +68.6% | — |
| LTM Mar 2026 | $112.39M USD | +18.7% | +21.8% | — | |
| LTM Mar 2026 | $91.08M USD | +0.9% | +1.3% | 253002.8% | |
| LTM Mar 2026 | $69.71M USD | +24.0% | +3.3% | — | |
| LTM Dec 2025 | $42.63M USD | +34.3% | +8.1% | — | |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $39.17M USD | — | +20.7% | — |
| LTM Mar 2026 | $35.1M USD | +30.0% | +33.8% | — | |
| LTM Mar 2026 | $26.25M USD | -41.9% | -7.4% | — | |
| Peer median (excluding NBP) | — | +18.7% | +10.7% | 253002.8% | |
Competitors are the stored peer set for NBP. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 · CNY | FY2022 Dec 2022 · CNY | FY2023 Dec 2023 · CNY | FY2024 Dec 2024 · CNY | FY2025 Dec 2025 · USD |
|---|---|---|---|---|---|
| Net Income | (2.33B) | (2.51B) | (208.18M) | (362.72M) | (88.34M) |
| Depreciation & Amortization | 34.14M | 63.82M | 1.06M | 7.14M | 856K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 608.61M | 357.15M | 10.26M | (14.23M) | 5.97M |
| Change in Working Capital | 394.52M | 552.06M | (37.2M) | (20.52M) | 17.07M |
| Accounts Receivables | 97.42M | 33.08M | 0 | 0 | 0 |
| Inventory | (27.24M) | 27.24M | 0 | 0 | 0 |
| Accounts Payables | 107.85M | 0 | 0 | 0 | 0 |
| Other Working Capital | 216.49M | 491.75M | (37.2M) | (20.52M) | 17.07M |
| Other Non-Cash Items | 321.18M | 431.48M | 161.2M | 5.9M | 43.84M |
| Operating Cash Flow | (973.09M) | (1.1B) | (72.85M) | (384.42M) | (20.6M) |
| Capital Expenditures | (29.93M) | (45.83M) | (164.35K) | (350.34K) | (7K) |
| Acquisitions (Net) | (6M) | 0 | 0 | 0 | 0 |
| Purchases of Investments | (10.17B) | (7.41B) | 0 | (1.79B) | (49.96M) |
| Sales of Investments | 9.48B | 7.91B | 0 | 801.66M | 154.89M |
| Other Investing Activities | 0 | 26K | (107.47M) | 452.53K | 47K |
| Investing Cash Flow | (727.21M) | 458.38M | (107.63M) | (992.42M) | 104.97M |
| Debt Repayment | 0 | 2.75M | 0 | 0 | 0 |
| Common Stock Issued | 0 | 0 | 0 | 0 | 61.91M |
| Common Stock Repurchased | 0 | (3.08M) | (8.66M) | (2.45M) | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 593.92M | 60.86M | 407.88K | 0 | (4.19M) |
| Financing Cash Flow | 593.92M | 42.36M | (8.25M) | (2.44M) | 57.73M |
| Effect of Forex Changes | (128.77M) | 389.2M | 36.89M | (327.04M) | 276K |
| Net Change in Cash | (1.24B) | (212.86M) | (151.58M) | (1.71B) | 142.37M |
| Free Cash Flow | (1B) | (1.15B) | (73.02M) | (384.77M) | (20.6M) |
NovaBridge Biosciences
NASDAQ:NBP
Intrinsic Alpha fair value
Locked
Current Price
$0.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.